Expression of the angiogenesis markers endocan in Cushing’s syndrome due to cortisol producing adenoma

• Published in: Endocrine 2023-03, Vol.79 (3), p.554-558
• Main Authors: Can, Mustafa, Kocabaş, Muhammet, Karaköse, Melia, Esen, Hacı Hasan, Kulaksızoğlu, Mustafa, Karakurt, Feridun
• Format: Article
• Language: English
• Subjects: Adenoma; Adenoma - surgery; Adrenal cortex; Adrenal Cortex - metabolism; Adrenocorticotropic hormone; Angiogenesis; Cortisol; Cushing Syndrome - diagnosis; Diabetes; Endocrinology; Humanities and Social Sciences; Humans; Hydrocortisone - metabolism; Internal Medicine; Medicine; Medicine & Public Health; multidisciplinary; Nervous system diseases; Original Article; Paraffin; Pituitary; Science; Tumors
• ISSN: 1559-0100; 1355-008X; 1559-0100
• DOI: 10.1007/s12020-022-03250-1

Purpose In this study, we aimed to investigate the endocan expression in tissue samples of patients diagnosed with Cushing’s syndrome (CS) due to Cortisol-Producing-Adenoma (CPA) and compare it with normal adrenal cortex tissue, and also to evaluate the correlations of endocan expression with clinical and histopathological features. Methods 11 patients who were operated for CS due to CPA between 2009–2021 and 14 control subjects with normal adrenal cortex were included in the study. Demographic, laboratory and clinicopathological data of the patients were recorded. Sections of 4–5 µm thickness were taken from paraffin blocks of patients diagnosed with CS due to CPA and control subjects with normal adrenal cortex tissue. The sections were then stained in a closed system automatic immunohistochemical staining device to perform immunohistochemical analysis. The endocan positive grade were determined based on the proportion of stained cells on a scale of negative to strong. Results The number of subjects with positive endocan expression and the mean endocan expression level in the CS group were significantly higher than the control group ( p  = 0.005, p